Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

被引:21
作者
Fabbro, Michel [1 ]
Colombo, Pierre-Emmanuel [2 ]
Leaha, Cristina Marinella [3 ]
Rouanet, Philippe [2 ]
Carrere, Sebastien [2 ]
Quenet, Francois [2 ]
Gutowski, Marian [2 ]
Mourregot, Anne [2 ]
D'Hondt, Veronique [1 ]
Coupier, Isabelle [4 ]
Vendrell, Julie [5 ]
Vilquin, Paul [5 ]
Pujol, Pascal [4 ]
Solassol, Jerome [5 ]
Mollevi, Caroline [6 ]
机构
[1] Univ Montpellier, Montpellier Canc Inst ICM, Med Oncol Dept, F-342983409 Montpellier, France
[2] Univ Montpellier, Montpellier Canc Inst ICM, Surg Oncol Dept, F-34298 Montpellier, France
[3] Univ Montpellier, Montpellier Canc Inst ICM, Pathol Dept, F-34298 Montpellier, France
[4] Univ Montpellier, Montpellier Hosp Univ, Oncogenet Dept, F-34298 Montpellier, France
[5] Univ Montpellier, Montpellier Hosp Univ, Solid Tumors Biol Dept, F-34298 Montpellier, France
[6] Univ Montpellier, Montpellier Canc Inst ICM, Biometr Unit, F-34298 Montpellier, France
关键词
high-grade serous ovarian cancer; conditional probability of survival; long-term survival; prognostic factors; MAINTENANCE THERAPY; DOUBLE-BLIND; CHEMOTHERAPY; CARCINOMA; EPIDEMIOLOGY; SURVEILLANCE; MORTALITY; SURGERY; LUNG;
D O I
10.3390/cancers12082184
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective:High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the prognostic factors of late relapses in HGSOC patients who survived >= five years, long-term survivors (LTS). The aim of our study is to assess the probability of survival according to the already survived time from diagnosis.Methods:Data from HGSOC patients treated between 1995 and 2016 were retrospectively collected to estimate the conditional probability of survival (CPS), probability of surviving Y years after diagnosis when the patient had already survived X years, and to determine the LTS prognostic factors. The primary endpoint was OS.Results:404 patients were included; 120 of them were LTS. Patients were aged 61 years (range: 20-89), WHO performance status 0-1 in 86.9% and 2 in 13.1%, and Federation Internationale de Gynecologie et d'Obstetrique (FIGO) staging III and IV in 82.7% and 17.3% patients. Breast cancer (BRCA) status was available in 116 patients (33% mutated), including 58 LTS (36% mutated). No macroscopic residual disease was observed in 58.4% patients. First-line platinum-based chemotherapy plus paclitaxel was administered in 80.4% of patients (median: six cycles (range: 1-14)). After a 9 point 3-year follow-up, median OS was four years (95% CI: 3.6-4.5). The CPS at five years after surviving one year was 42.8% (95% CI: 35.3-48.3); it increased to 81.7% (95% CI: 75.5-87.8) after four survived years. Progression-free interval>18 months was the only LTS prognostic factor in the multivariable analysis (hazard ratio (HR) = 0.23; 95% CI: 0.13-0.40;p< 0.001).Conclusion:The CPS provided relevant and encouraging clinical information on the life expectancy of HGSOC patients who already survived a period of time after diagnosis. LTS prognostic factors are useful for clinicians and patients.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 41 条
[1]   Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis [J].
Bristow, Robert E. ;
Puri, Isha ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :265-274
[2]   Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial [J].
Buys, Saundra S. ;
Partridge, Edward ;
Black, Amanda ;
Johnson, Christine C. ;
Lamerato, Lois ;
Isaacs, Claudine ;
Reding, Douglas J. ;
Greenlee, Robert T. ;
Yokochi, Lance A. ;
Kessel, Bruce ;
Crawford, E. David ;
Church, Timothy R. ;
Andriole, Gerald L. ;
Weissfeld, Joel L. ;
Fouad, Mona N. ;
Chia, David ;
O'Brien, Barbara ;
Ragard, Lawrence R. ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hartge, Patricia ;
Pinsky, Paul F. ;
Zhu, Claire S. ;
Izmirlian, Grant ;
Kramer, Barnett S. ;
Miller, Anthony B. ;
Xu, Jian-Lun ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2295-2303
[3]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[4]   Practical Application of a Calculator for Conditional Survival in Colon Cancer [J].
Chang, George J. ;
Hu, Chung-Yuan ;
Eng, Cathy ;
Skibber, John M. ;
Rodriguez-Bigas, Miguel A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :5938-5943
[5]   Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001 [J].
Choi, Mehee ;
Fuller, Clifton D. ;
Thomas, Charles R., Jr. ;
Wang, Samuel J. .
GYNECOLOGIC ONCOLOGY, 2008, 109 (02) :203-209
[6]   Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].
Coleman, R. L. ;
Fleming, G. F. ;
Brady, M. F. ;
Swisher, E. M. ;
Steffensen, K. D. ;
Friedlander, M. ;
Okamoto, A. ;
Moore, K. N. ;
Ben-Baruch, N. Efrat ;
Werner, T. L. ;
Cloven, N. G. ;
Oaknin, A. ;
DiSilvestro, P. A. ;
Morgan, M. A. ;
Nam, J. -H. ;
Leath, C. A., III ;
Nicum, S. ;
Hagemann, A. R. ;
Littell, R. D. ;
Cella, D. ;
Baron-Hay, S. ;
Garcia-Donas, J. ;
Mizuno, M. ;
Bell-McGuinn, K. ;
Sullivan, D. M. ;
Bach, B. A. ;
Bhattacharya, S. ;
Ratajczak, C. K. ;
Ansell, P. J. ;
Dinh, M. H. ;
Aghajanian, C. ;
Bookman, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415
[7]   Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Coleman, Robert L. ;
Oza, Amit M. ;
Lorusso, Domenico ;
Aghajanian, Carol ;
Oaknin, Ana ;
Dean, Andrew ;
Colombo, Nicoletta ;
Weberpals, Johanne, I ;
Clamp, Andrew ;
Scambia, Giovanni ;
Leary, Alexandra ;
Holloway, Robert W. ;
Amenedo Gancedo, Margarita ;
Fong, Peter C. ;
Goh, Jeffrey C. ;
O'Malley, David M. ;
Armstrong, Deborah K. ;
Garcia-Donas, Jesus ;
Swisher, Elizabeth M. ;
Floquet, Anne ;
Konecny, Gottfried E. ;
McNeish, lain A. ;
Scott, Clare L. ;
Cameron, Terri ;
Maloney, Lara ;
Isaacson, Jeff ;
Goble, Sandra ;
Grace, Caroline ;
Harding, Thomas C. ;
Raponi, Mitch ;
Sun, James ;
Lin, Kevin K. ;
Giordano, Heidi ;
Ledermann, Jonathan A. .
LANCET, 2017, 390 (10106) :1949-1961
[8]   Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer [J].
Colombo, P. E. ;
Labaki, M. ;
Fabbro, M. ;
Bertrand, M. ;
Mourregot, A. ;
Gutowski, M. ;
Saint-Aubert, B. ;
Quenet, F. ;
Rouanet, P. ;
Mollevi, C. .
GYNECOLOGIC ONCOLOGY, 2014, 135 (02) :223-230
[9]   Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients [J].
Colombo, P. -E. ;
Mourregot, A. ;
Fabbro, M. ;
Gutowski, M. ;
Saint-Aubert, B. ;
Quenet, F. ;
Gourgou, S. ;
Rouanet, P. .
EJSO, 2009, 35 (02) :135-143
[10]  
Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO